Company profile
HOOKIPA Pharma Inc.
OTC: HOOK · Healthcare · Biotechnology
#451 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 32GM —SS 48
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), 3-yr revenue growth · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$14.9M
Rev growth YoY (TTM)
-71.5%
Net income (FY)
-$43.5M
Employees
82
as of 2026-08-22
Market cap
$14.4M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$43.9M$43.9M2024
Net income-$43.5M-$43.5M2024
Operating income-$51.5M-$51.5M2024
Total assets$82.5M$82.5M2024
Liabilities$31.3M$31.3M2024
Equity$51.2M$51.2M2024
Revenue trend
FY2020 – FY2024 · USD
FY20
FY20
FY20
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2023
By product
Grant100%
By geography
Not disclosed.
The read
What is HOOKIPA Pharma Inc.’s revenue?
HOOKIPA Pharma Inc. booked $43.9M in FY2024 revenue, growing 118% year over year — faster than most Healthcare companies we track, at a -99.0% net margin.
Peers · Healthcare
Cumberland Pharmaceuticals Inc.70BNew York Health Care, Inc.——SANUWAVE Health Inc.74BXilio Therapeutics, Inc.38DMedAvail Holdings, Inc.——Wave Life Sciences Ltd.63CNeighbors
New York →Key facts
CEOMalte Peters
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
ExchangeOTC: HOOK
Employees82
IPO date2019-04-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.